Epigenetic signatures in breast cancer: Clinical perspective

Breast Care

Volumn 5, Issue 2, 2010, Pages 66-73

  Parrella, Paola ^a,b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Oncology Laboratory   (Italy)

Author keywords

Breast cancer; DNA methylation; Early detection

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; ZEBULARINE;

BREAST CANCER; CANCER GROWTH; CELL DIFFERENTIATION; CELL DIVISION; CPG ISLAND; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; TISSUE SPECIFICITY;

EID: 77952798832     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000309138     Document Type: Review

References (59)

1. Esteller M: Epigenetics in cancer. N Engl J Med 2008;358:1148-1159.
2. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3: 415-428.
3. Okano M, Bell DW, Haber DA, Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247-257.
4. Holliday R: DNA methylation and epigenetic inheritance. Philos Trans R Soc Lond B Biol Sci 1990; 326:329-338.
5. Wade PA: Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene 2001;20:3166-3173.
6. Gregory PD, Wagner K, Horz W: Histone acetylation and chromatin remodeling. Exp Cell Res 2001; 265:195-202.
7. Witcher M, Emerson BM: Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 2009;34:271-284.
8. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-749.
9. Adams JM, Kelly PN, Dakic A, Carotta S, Nutt SL, Strasser A: Role of 'cancer stem cells' and cell survival in tumor development and maintenance. Cold Spring Harb Symp Quant Biol 2008;73:451-459.
10. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, et al.: Epigenetic stem cell signature in cancer. Nat Genet 2007;39:157-158.
11. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463.
12. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, et al.: Preferential response of cancer cells to zebularine. Cancer Cell 2004;6:151-158.
13. Kristensen LS, Nielsen HM, Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625:131-142.
14. Bicaku E, Marchion DC, Schmitt ML, Munster PN: Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 2008;68:1513-1519.
15. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, et al.: Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009;15:91-99.
16. Mai A, Altucci L: Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009;41:199-213.
17. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229.
18. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, et al.: Aberrant CpG-island methylation has non-random and tumour-typespecific patterns. Nat Genet 2000;24:132-138.
19. Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, et al.: Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004;10:5349-5354.
20. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR: Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000;60:4346- 4348.
21. Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E: Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res 2004;10:5998-6005.
22. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H: Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-612.
23. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC: RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 2009;113:113-121.
24. Hoque MO, Prencipe M, Poeta ML, Barbano R, Valori VM, Copetti M, Gallo AP, Brait M, Maiello E, Apicella A, et al.: Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009;18:2694-2700.
25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-9826.
26. Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM: Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation- specific polymerase chain reaction. Cancer Res 1999;59:3899-3903.
27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59: 225-249.
28. Barrows GH, Anderson TJ, Lamb JL, Dixon JM: Fine-needle aspiration of breast cancer. Relationship of clinical factors to cytology results in 689 primary malignancies. Cancer 1986;58:1493-1498.
29. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP: Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 2003;16:1095-1101.
30. Jeronimo C, Costa I, Martins MC, Monteiro P, Lisboa S, Palmeira C, Henrique R, Teixeira MR, Lopes C: Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003;9:3413-3417.
31. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, et al.: Detection of breast cancer cells in ductal lavage fluid by methylationspecific PCR. Lancet 2001;357:1335-1336. (Pubitemid 32441534)
32. Muller HM, Widschwendter M: Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn 2003;3:443-458.
33. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al- Saleem T, Cairns P: Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004;10:6189-6193. (Pubitemid 39287525)
34. Shukla S, Mirza S, Sharma G, Parshad R, Gupta SD, Ralhan R: Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 2006;1:88-93.
35. Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, Ralhan R: Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007;81:280-287.
36. Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R: Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007;80:1873-1881. (Pubitemid 46562520)
37. Taback B, Giuliano AE, Lai R, Hansen N, Singer FR, Pantel K, Hoon DS: Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann N Y Acad Sci 2006; 1075:211-221.
38. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, et al.: Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006;24:4262-4269. (Pubitemid 46630783)
39. Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES: Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer 2009;125:2887-2892.
40. Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES: Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Clin Biochem 2009;42:970-975
41. Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES: Kallikrein
42. (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann Oncol 2009;20: 1020-1025.
43. Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R, Dahl E: Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 2008;29:991-998.
44. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knuchel R, Dahl E: Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 2008;8:154.
45. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003;63:7641-7645.
46. Muller HM, Fiegl H, Widschwendter A, Widschwendter M: Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci 2004;1022:44-49. (Pubitemid 38951580)
47. Jing F, Jun L, Yong Z, Wang Y, Fei X, Zhang J, Hu L: Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology 2008;75:60-66.
48. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, et al.: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005;65:4101-4117.
49. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004;64: 3807-3813.
50. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M: Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005;65:1141-1145.
51. Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, Dowsett M, Mueller- Holzner E, Windbichler G, Daxenbichler G, et al.: Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res 2008;14:3494-3502.
52. Maier S, Nimmrich I, Koenig T, Eppenberger- Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nahrig J, et al.: DNAmethylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients - technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer 2007;43:1679-1686.
53. Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, et al.: DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 2008;111:429-437.
54. Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, et al.: DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2009;15:315-323.
55. Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, Walter B, Hofstadter F, Buttner R, Muller SC, et al.: Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010;70:61-69.
56. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, Ariyan S, Narayan D, Bacchiocchi A, Molinaro A, et al.: Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009;4:e4563.
57. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al.: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-610.
58. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E: Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous Tcell lymphoma. Histopathology 2008;53:267-277.
59. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, et al.: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009;69:3802-3809.